News & Updates

Torsemide, furosemide yield similar survival outcomes in heart failure

30 Jan 2023

Treatment with torsemide in survivors of heart failure hospitalization appears to have a similar effect on all-cause mortality over 12 months as furosemide, according to data from the open-label TRANSFORM-HF study.

Torsemide, furosemide yield similar survival outcomes in heart failure

30 Jan 2023

Switching from ARB, ACEI to sacubitril/valsartan ups angioedema risk

29 Jan 2023

New users of sacubitril-valsartan (SV) show no increased risk of angioedema when compared to users of angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB), reports a study.

Switching from ARB, ACEI to sacubitril/valsartan ups angioedema risk

29 Jan 2023

Some antihypertensive medications may lower dementia risk

24 Jan 2023 by

Use of angiotensin II (ATII)-stimulating antihypertensive medication (AHM), angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (CCBs) helps reduce the risk of dementia over a decade, but this beneficial effect decreases over time, according to a study.

Some antihypertensive medications may lower dementia risk

24 Jan 2023

Finerenone reduces SBP in diabetic patients with CKD

23 Jan 2023

Treatment with finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life, results in decreased 24-h, daytime, and night-time systolic blood pressure (SBP), results of a study have shown.

Finerenone reduces SBP in diabetic patients with CKD

23 Jan 2023

ADHD medication use carries no excess cardiovascular disease risk

22 Jan 2023

Attention-deficit/hyperactivity disorder (ADHD) medications do not appear to put users at increased risk of cardiovascular disease (CVD), although a modest risk increase for cardiac arrest or tachyarrhythmias cannot be ruled out, according to the results of a meta-analysis.

ADHD medication use carries no excess cardiovascular disease risk

22 Jan 2023

IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension

21 Jan 2023

Use of intravenous (IV) antihypertensive treatment appears to increase the risk of myocardial injury in patients who develop severe hypertension during hospitalization and without acute target end organ damage, reveals a recent study.

IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension

21 Jan 2023

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023 by

While current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with non-valvular atrial fibrillation (NVAF), there is a lack of head-to-head trial data to guide the choice of DOAC. Esteemed expert Dr Teo Wee Siong, Consultant Cardiologist & Cardiac Electrophysiologist from Mount Elizabeth Medical Centre, Singapore, reviewed the latest data on the comparative effectiveness and safety of DOACs in AF, provided valuable insights on considerations for the selection of DOACs, and shared his clinical experience with apixaban (Eliquis, Pfizer).

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

21 Jan 2023

Omega-3 supplements lower triglyceride levels in postmenopausal women

20 Jan 2023

Supplementation with omega-3 fatty acids helps reduce triglyceride levels in postmenopausal women, according to a study. This supplement also leads to a modest increase in high- (HDL-C) and low-density lipoprotein cholesterol (LDL-C).

Omega-3 supplements lower triglyceride levels in postmenopausal women

20 Jan 2023

Low baroreflex sensitivity tied to higher BP, BP variability

20 Jan 2023

Lower cardiovagal baroreflex sensitivity (BRS) appears to contribute to a higher mean blood pressure (BP) from the short- to midterm range and to BP variability, albeit not consistently, results of the Maastricht study have shown.

Low baroreflex sensitivity tied to higher BP, BP variability

20 Jan 2023

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023 by

The mortality rate following an incidence of out-of-hospital cardiac arrest (OHCA) is highest in the first 3 years post-event, gradually reducing over time, according to a study from Singapore.

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023

News & Updates

Filter by Specialty:

Specialty:

Torsemide, furosemide yield similar survival outcomes in heart failure

Torsemide, furosemide yield similar survival outcomes in heart failure

Switching from ARB, ACEI to sacubitril/valsartan ups angioedema risk

Switching from ARB, ACEI to sacubitril/valsartan ups angioedema risk

Some antihypertensive medications may lower dementia risk

Some antihypertensive medications may lower dementia risk

Finerenone reduces SBP in diabetic patients with CKD

Finerenone reduces SBP in diabetic patients with CKD

ADHD medication use carries no excess cardiovascular disease risk

ADHD medication use carries no excess cardiovascular disease risk

IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension

IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding

Omega-3 supplements lower triglyceride levels in postmenopausal women

Omega-3 supplements lower triglyceride levels in postmenopausal women

Low baroreflex sensitivity tied to higher BP, BP variability

Low baroreflex sensitivity tied to higher BP, BP variability

Death after out-of-hospital cardiac arrest highest within first 3 years

Death after out-of-hospital cardiac arrest highest within first 3 years